Oncology · Breast CancerTrial Updateclinicalmid-term

Phase II Study of HER2 Imaging as Biomarker for T-DM1 in Advanced Breast Cancer

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 6:02:10 AM

Assessment confidence: 62% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ZEPHIR-02 trial's focus on HER2 imaging as a predictive biomarker could significantly influence treatment sequencing in HER2-positive breast cancer. If successful, it may establish HER2-PET/CT as a standard biomarker, impacting future treatment guidelines and competitive dynamics for Roche's T-DM1. Regulatory context from FDA (FDA AP — ONTRUZANT (SUPPL)) supports the near-term read. Assessment grounded in 11 ranked evidence items (4 high-relevance).

Strategic Assessment

Success in this trial may validate HER2-PET/CT as a standard biomarker, impacting future treatment guidelines and competitive positioning for Roche's T-DM1. The strongest clinical anchor is HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ClinicalTrials.gov), sub-indication match (her2); mechanism alignment (her2). In her2, 4 regulatory and 0 competitive items passed relevance filtering for Roche.

Competitive Pressure

The most relevant competitive pressure comes from This study could influence treatment sequencing strategies for HER2-positive breast cancer, particularly regarding the use of T-DM1 after trastuzumab deruxtecan..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ONTRUZANT (SUPPL) (FDA). Sponsor/company relevance (Roche); Regulatory pathway relevance (nda). Success in this trial may lead to updates in treatment guidelines and regulatory considerations for biomarker use in HER2-positive breast cancer therapies.

Key Risks

Elevated medium regulatory exposure for Roche could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The validation of HER2-PET/CT could enhance the positioning of T-DM1 in treatment protocols, potentially increasing market share and revenue for Roche in the oncology sector.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Upside for Roche may improve if HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Jazz Pharmaceuticals. Collaborators: Jazz Pharmaceuticals Ireland Limited.
Success in this trial may validate HER2-PET/CT as a standard biomarker, impacting future treatment guidelines and competitive positioning for Roche's T-DM1.

What Would Change This Assessment

This becomes more urgent if Monitor enrollment progress, interim results on treatment responses, and any updates on metabolic evaluations from the trial.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ONTRUZANT (SUPPL)
FDAmedium relevance
Sponsor/company relevance (Roche); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PHESGO (SUPPL)
FDAmedium relevance
Sponsor/company relevance (Roche); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HERCEPTIN HYLECTA (SUPPL)
FDAmedium relevance
Sponsor/company relevance (Roche); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ONTRUZANT (SUPPL)
FDAmedium relevance
Sponsor/company relevance (Roche); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ENHERTU (SUPPL)
FDAlow relevance
Sponsor/company relevance (Roche)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Sponsor/company relevance (Roche)
FDA document
View source

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
FDA document
View source
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
FDA document
View source
Study of Voicing My CHOiCES as Tool for Advanced Care Planning in Young Adults With Cancer
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govlow relevance
Sponsor/company relevance (Roche)
FDA document
View source

No evidence in this category.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
FDA document
View source
STARD10 promotes progression of HER2+ breast cancer and intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling axis.
PubMedhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Roche
T-DM1
HER2-positive breast cancer

Commercial impact

high

The validation of HER2-PET/CT could enhance the positioning of T-DM1 in treatment protocols, potentially increasing market share and revenue for Roche in the oncology sector.

Regulatory impact

medium

Success in this trial may lead to updates in treatment guidelines and regulatory considerations for biomarker use in HER2-positive breast cancer therapies.

What to watch

Monitor enrollment progress, interim results on treatment responses, and any updates on metabolic evaluations from the trial.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.

Signals